|Bid||45.00 x 900|
|Ask||45.00 x 1300|
|Day's Range||43.50 - 66.14|
|52 Week Range||4.14 - 132.00|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Annovis Bio's Alzheimer's drug failed to significantly outperform the placebo in a midstage test, leading ANVS stock to plummet on Thursday.
In this article, we will discuss the 11 best pharma and biotech stocks to buy according to Jim Simons’ Euclidean Capital. If you want to skip our detailed analysis of Simons’ history, investment philosophy, and hedge fund performance, go directly to the 5 Best Pharma and Biotech Stocks to Buy According to Jim Simons’ Euclidean […]
Annovis bucked the trend depressing Alzheimer's stocks on Friday as ANVS stock touched a record high while SAVA stock and INMB stock fell.